- Home
- DOCN vs RYTM Comparison
DOCN vs RYTM Comparison
Compare DOCN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCN
- RYTM
- Stock Information
- Founded
- DOCN 2011
- RYTM 2008
- Country
- DOCN United States
- RYTM United States
- Employees
- DOCN N/A
- RYTM N/A
- Industry
- DOCN Retail: Computer Software & Peripheral Equipment
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- DOCN Technology
- RYTM Health Care
- Exchange
- DOCN Nasdaq
- RYTM Nasdaq
- Market Cap
- DOCN 3.7B
- RYTM 3.2B
- IPO Year
- DOCN 2021
- RYTM 2017
- Fundamental
- Price
- DOCN $34.18
- RYTM $54.80
- Analyst Decision
- DOCN Buy
- RYTM Strong Buy
- Analyst Count
- DOCN 13
- RYTM 12
- Target Price
- DOCN $43.17
- RYTM $68.58
- AVG Volume (30 Days)
- DOCN 1.1M
- RYTM 532.5K
- Earning Date
- DOCN 05-09-2025
- RYTM 05-06-2025
- Dividend Yield
- DOCN N/A
- RYTM N/A
- EPS Growth
- DOCN 345.00
- RYTM N/A
- EPS
- DOCN 0.89
- RYTM N/A
- Revenue
- DOCN $780,615,000.00
- RYTM $130,126,000.00
- Revenue This Year
- DOCN $15.41
- RYTM $47.06
- Revenue Next Year
- DOCN $13.66
- RYTM $68.10
- P/E Ratio
- DOCN $38.39
- RYTM N/A
- Revenue Growth
- DOCN 12.66
- RYTM 68.06
- 52 Week Low
- DOCN $26.63
- RYTM $35.17
- 52 Week High
- DOCN $47.02
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- DOCN 35.55
- RYTM 53.63
- Support Level
- DOCN $35.71
- RYTM $52.54
- Resistance Level
- DOCN $38.12
- RYTM $55.87
- Average True Range (ATR)
- DOCN 1.33
- RYTM 2.15
- MACD
- DOCN -0.13
- RYTM 0.47
- Stochastic Oscillator
- DOCN 15.27
- RYTM 86.57
About DOCN DigitalOcean Holdings Inc.
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups, and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. Geographically, the company generates maximum revenue from North America and also has a presence in Europe, Asia, and the Rest of the world.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.